Recipharm’s Post

https://buff.ly/3VsgMLb 𝐅𝐃𝐀'𝐬 𝐎𝐩𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐖𝐚𝐫𝐩 𝐒𝐩𝐞𝐞𝐝 2.0: 𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐑𝐚𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 🚀🔬 💠 The FDA is taking a page from Operation Warp Speed with its new pilot program, START, designed to accelerate the development of rare disease therapies. This initiative brings together the FDA and seven leading biotech companies to streamline the approval process and bring much-needed treatments to patients faster. 💠 By fostering close collaboration between regulators and drug developers, START aims to optimize clinical trial design, refine patient selection, and enhance communication throughout the development process. 💠 Companies like Denali Therapeutics, Larimar Therapeutics, Grace Science, Neurogene, and Myrtelle are already participating in the program, working on groundbreaking therapies for a variety of rare conditions. 💠 I see this as a much-needed step in the right direction to help sponsors deal with the difficulties in drug development in this area as a result of small patient populations, lack of established endpoints, and the complexities of patient recruitment and retention. #FDA #RareDisease #Biotech #Innovation #DrugDevelopment #orphandrugs

Thoughts on this? >> Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #productmarketing #biotech #pharmaceutical

Thoughts on this? >> Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharma #healthcare #pharmaceutical

How do you precisely control the timing and location of therapeutic protein expression within a patient’s body? Strand Therapeutics is developing first-in-class programmable mRNA therapeutics. To speed up their process development, Strand’s R&D team uses Benchling to ✔️ Eliminate data silos ✔️ Enhance data capture and standardization ✔️ Connect process and analytical data on a centralized platform https://lnkd.in/eyQHz6Pe #BuiltOnBenchling

Fascinating to see the moves being made in the trispecific antibody space! #trispecific #bispecific #antibody #antibodytherapy #lifesciences #marketresearch #consulting #ipsen #gilead #merck

Exciting developments and insights emerged from this year's JPMorgan Healthcare Conference, providing a snapshot of the biopharma’s trajectory. Here are some highlights from Greg Slabdokin’s takeaways. • Triumvira Immunologics, Inc.’s president and COO Robert Williamson shares insight on how the FDA’s investigation on CAR T cell therapies. • Halia Therapeutics, Inc.'s CEO David Bearss Ph.D. comments on the challenges of 2023 and how the biopharma industry is cautiously optimistic, turning a corner with renewed enthusiasm for the sector's improved outlook in 2024. • Codagenix Inc.'s CEO Paul Grint shares updates on their work in the COVID-19 vaccine space. Read the full article on BioSpace for detailed insights into industry trends, upcoming trials, and strategic moves by key players. https://bit.ly/3SqKSvU #JPM2024 #Biopharma #Innovation #Healthcare

📣 | Newcells Biotech launches high-content and high-throughput imaging suite to advance pre-clinical drug development programmes. We are delighted to announce the launch of our new imaging suite and advanced lung Fibroblast-to-Myofibroblast Transition (FMT) assay. Comprising high-content and high-throughput equipment, the state-of-the-art imaging suite will provide more in-depth and robust in vitro data. The advanced high-throughput high-sensitivity lung FMT assay facilitates customisable and rapid assessment of the efficacy of anti-fibrotic drug candidates. 💬 “The launch of our new imaging suite and enhanced fibrotic disease screening assay is a key step in our strategy to provide innovative, market-leading in vitro models that advance the discovery and safe development of new drugs." - Dr Mike Nicholds, CEO and Co-Founder, Newcells Biotech Read the full press release to learn more: https://lnkd.in/gNBAEP3e #Newcells #DrugDevelopment #FMT #InVitroData #HighContentImaging

InMed's INM-901 is a small molecule drug candidate demonstrating multiple pharmacological effects in the potential treatment of #Alzheimer's disease. Watch this video presentation by InMed’s CEO, Eric A. Adams, as he shares the preclinical data on INM-901: https://ow.ly/Vlls50T2ygH $INM #AlzheimersDisease

Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki and Sinan Sarac share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: https://lnkd.in/etSKQC_F #PrecisionOncology #NovelInsights

Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki and Sinan Sarac share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: https://lnkd.in/g-vJa8Ts #PrecisionOncology #ParexelBiotech #NovelInsights